BioSpace News Archive

Wandercraft, the developer of the world’s first self-balancing robotic exoskeleton that enables people with limited mobility to stand up and walk again, announced today that it has received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries (SCI) at levels T5 to L5.

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2023.

Vaxxinity, Inc. today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024) , taking place March 5-9, 2024.

CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC) today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company’s lead product candidate, Auxora™

HemoSonics, LLC announced that its Quantra Hemostasis System with QPlus® and QStat® Cartridges has been named a finalist in the 2024 Edison™ Awards.

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference.

Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces that the first patient has been dosed in the Company’s Phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof of mechanism trial in psoriasis.

VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.

Kenvue Inc. today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne.